NICE, the health technology appraisal body for England, has rejected Roche’s Tecentriq (atezolizumab) for small-cell lung cancer, saying there are uncertainties over the duration of the treatment effect and overall survival and that the treatment does not represent a cost-effective use of National Health Service resources.
The recommendation Roche had sought was for routine NHS funding of Tecentriq in combination with carboplatin and etoposide for untreated...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?